ArticleBlood2022
Monoclonal and oligoclonal anti-platelet factor 4 antibodies mediate VITT.
Open access · bronzeAbstract read
In one paragraph
Article in Blood, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
13.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 64 citations in OpenAlex.
- Monoclonal Gammopathy of Thrombotic Significance.American journal of hematology · 2026Review
- Pathogenic PF4/Polyanion ELISA-Negative Antibodies in HIT.American journal of hematology · 2026Article
- Platelet factor 4 antibody persistence and long-term pathogenicity in vaccine-induced immune thrombotic thrombocytopenia.Journal of thrombosis and haemostasis : JTH · 2026Article
- Anti-Platelet Factor 4 Antibody Clonal Heterogeneity and MGUS Status in HIT.medRxiv : the preprint server for health sciences · 2026Article
- Translational immunothrombosis in autoimmune Heparin-Induced thrombocytopenia: targeting the FcγRIIa-Syk-BTK and complement pathways.Clinical and experimental medicine · 2026Review
- Adenoviral Inciting Antigen and Somatic Hypermutation in VITT.The New England journal of medicine · 2026Observational
- Microfluidic Electrochemical Biosensor for the Detection of Platelet Factor 4 Antibody-Mediated Thrombotic Disorders.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- The Immunology of Transfusion Medicine: Past, Present, and Future.Methods in molecular biology (Clifton, N.J.) · 2026Review
- Platelet factor 4 in cognitive, immune and hematopoietic aging: emerging evidence and translational challenges.Frontiers in immunology · 2026Review
- Platelet Factor 4 Antibody Persistence and Long-term Pathogenicity in Vaccine-induced Immune Thrombotic Thrombocytopenia.medRxiv : the preprint server for health sciences · 2025Article
- Diagnostic Reassessment of a Historical Case of Atypical Heparin-Induced Thrombocytopenia: Between Spontaneous Heparin-Induced Thrombocytopenia and a Vaccine-Induced Immune Thrombotic Thrombocytopenia-Like Syndrome.Life (Basel, Switzerland) · 2025Article
- Pathogenic PF4/Polyvinylsulfonate ELISA-negative Antibodies in HIT.medRxiv : the preprint server for health sciences · 2025Article
- Monoclonal Antibodies in the Pathogenesis of Heparin-Induced Thrombocytopenia.The New England journal of medicine · 2025Article
- Anti-PF4 disorders: Pathogenesis, diagnosis and treatment.British journal of haematology · 2025Review
- Cooperative effect between anti-PF4/H and anti-PF4 antibodies increases cell activation and thrombotic risk in HIT.Blood advances · 2025Article
- VITT Pathophysiology: An Update.Vaccines · 2025Review
- Next-Generation Adenoviral Vector-Based Vaccines for Severe Acute Respiratory Syndrome Coronavirus-2.Vaccines · 2025Review
- Prothrombotic antibodies targeting the spike protein's receptor-binding domain in severe COVID-19.Blood · 2025Article
- COVID-19 vaccine-induced immune thrombotic thrombocytopenia: pathophysiology and diagnosis.Annals of hematology · 2025Review
- Advances in our understanding of anti-PF4 related immunothrombosis.Frontiers in immunology · 2025Review
Corrections and comments
- Update of
Authors and funding
16 authors at 6 institutions in 2 countries.
Adam J KanackDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
Antonios BayasDepartment of Neurology and Clinical Neurophysiology, University Hospital of Augsburg, Augsburg, Germany.
Gemlyn GeorgeDepartment of Medicine, University of Colorado, Aurora, CO.
Mouhamed Yazan Abou-IsmailDepartment of Medicine and.ORCID 0000-0002-6682-4366
Bandana SinghDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
Mindy C KohlhagenDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
Noah P SplinterDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
Monika ChristDepartment of Neurology and Clinical Neurophysiology, University Hospital of Augsburg, Augsburg, Germany.
Markus NaumannDepartment of Neurology and Clinical Neurophysiology, University Hospital of Augsburg, Augsburg, Germany.
Karen A MoserDepartment of Pathology, University of Utah Health Sciences Center, Salt Lake City, UT.
Kristi J SmockDepartment of Pathology, University of Utah Health Sciences Center, Salt Lake City, UT.ORCID 0000-0003-0304-6461
Alison GrazioliNational Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.
Renren WenBlood Research Institute, Versiti, Milwaukee, WI.ORCID 0000-0003-2420-8212
Demin WangBlood Research Institute, Versiti, Milwaukee, WI.
David L MurrayDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
Anand PadmanabhanDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.ORCID 0000-0003-2519-4377
Mayo Clinic in Arizona · USUniversity Hospital Augsburg · DEUniversity of Utah · USVersiti Blood Center of Wisconsin · USUniversity of Colorado Anschutz Medical Campus · USUniversity of Maryland, Baltimore · US
Funding
B cell responses in heparin-induced thrombocytopeniaR01HL130724 · NHLBI · VERSITI WISCONSIN, INC. · PI WANG, DEMIN · 2017 to 2024
$4.8MMolecular Basis of the Humoral Immune Response in Heparin-Induced ThrombocytopeniaR01HL148120 · NHLBI · VERSITI WISCONSIN, INC. · PI Renren Wen · 2019 to 2026
$3.8MB-cell response and thrombotic complications in COVID-19R01HL161127 · NHLBI · VERSITI WISCONSIN, INC. · PI WEN, RENREN · 2022 to 2025
$2.6MNew approaches to the pathophysiology, diagnosis and management of heparin-induced thrombocytopeniaR01HL158932 · NHLBI · MAYO CLINIC ROCHESTER · PI PADMANABHAN, ANAND · 2021 to 2025
$2.0MNew Approaches to Pathogenesis and Diagnosis of Heparin-Induced Thrombocytopenia (HIT)K08HL133479 · NHLBI · VERSITI WISCONSIN, INC. · PI PADMANABHAN, ANAND · 2017 to 2021
$836kNHLBI NIH HHS K08 HL133479NHLBI NIH HHS R01 HL130724NHLBI NIH HHS R01 HL148120NHLBI NIH HHS R01 HL158932NHLBI NIH HHS R01 HL161127
Abstract
PubMed holds no abstract for this paper.
Indexed as
Platelet Factor 4Purpura, Thrombocytopenic, IdiopathicAntibodies, MonoclonalHumansImmunoglobulin GImmunologic FactorsAntibodies, MonoclonalImmunoglobulin GImmunologic FactorsPlatelet Factor 4
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.